Literature DB >> 11590319

Expression of p57/Kip2 protein in pancreatic adenocarcinoma.

Y Ito1, T Takeda, K Wakasa, M Tsujimoto, N Matsuura.   

Abstract

INTRODUCTION: Evaluation of the biologic character of carcinomas requires understanding of cell cycle regulators. AIMS: To investigate p57 expression in human pancreatic adenocarcinoma and cyst adenoma.
METHODOLOGY: We examined the expression of p57(Kip2), a member of the Cip/Kip family, in 45 pancreatic adenocarcinomas, 7 cystadenomas, and 7 chronic pancreatitis cases.
RESULTS: The p57 labeling index (LI) in duct epithelia in chronic pancreatitis averaged 32.8+/-8.3 and was significantly higher than in normal duct epithelia (18.8+/-6.6; p = 0.0011). For the carcinoma, the LI averaged 46.0+/-20.9, which was significantly higher than that for normal duct epithelia (p < 0.0001) and cystadenoma (16.0 11.2; p = 0.0007). However, it was significantly reduced in cases with stage IV disease (p = 0.0351), lymph node metastasis (p = 0.0003), larger size (p = 0.0094), capsular invasion (p = 0.0462), lymphatic invasion (p = 0.0351), and cell proliferating activity (p = 0.0002). In multivariate analysis, p57 LI in pancreatic adenocarcinoma was independently linked to high proliferating activity (p = 0.0230).
CONCLUSION: These results suggest that p57 plays a role in the hyperplastic change of the ducts in chronic pancreatitis and that pS7 overexpression contributes to the downregulation of cell proliferation, and its decreased expression contributes to the progression of pancreatic adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11590319     DOI: 10.1097/00006676-200110000-00004

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  6 in total

1.  Expression of cell cycle regulator p57kip2, cyclinE protein and proliferating cell nuclear antigen in human pancreatic cancer: an immunohistochemical study.

Authors:  Hui Yue; Hui-Yong Jiang
Journal:  World J Gastroenterol       Date:  2005-08-28       Impact factor: 5.742

2.  Expression of p57kip2, Rb protein and PCNA and their relationships with clinicopathology in human pancreatic cancer.

Authors:  Hui Yue; Yan-Li Na; Xin-Li Feng; Shu-Ren Ma; Fu-Lin Song; Bo Yang
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

3.  Expression of p15INK⁴b and p57KIP² and relationship with clinicopathological features and prognosis in patients with vulvar squamous cell carcinoma.

Authors:  Ruth Holm; Mette Førsund; Mai T Nguyen; Jahn M Nesland; Claes G Trope
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

4.  CDKN1C/p57kip2 is a candidate tumor suppressor gene in human breast cancer.

Authors:  Pamela S Larson; Benjamin L Schlechter; Chia-Lin King; Qiong Yang; Chelsea N Glass; Charline Mack; Robert Pistey; Antonio de Las Morenas; Carol L Rosenberg
Journal:  BMC Cancer       Date:  2008-03-06       Impact factor: 4.430

5.  A mechanistic role for the chromatin modulator, NAP1L1, in pancreatic neuroendocrine neoplasm proliferation and metastases.

Authors:  Simon Schimmack; Andrew Taylor; Ben Lawrence; Daniele Alaimo; Hubertus Schmitz-Winnenthal; Markus W Büchler; Irvin M Modlin; Mark Kidd
Journal:  Epigenetics Chromatin       Date:  2014-07-21       Impact factor: 4.954

6.  Correlation of CA19-9 and P57 (KiP2) Expression with Tumor Grade and Invasive Front in Oral Squamous Cell Carcinoma.

Authors:  Fatemeh Mashhadiabbas; Moones Rajabi; Mohammad Javad KharaziFard; Hamidreza Moslemi
Journal:  J Dent (Shiraz)       Date:  2018-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.